ArticlePharmacology research & perspectives2023

Mechanistic in vitro studies indicate that the clinical drug-drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal BCRP and hepatic OATP1B1 with minimal contribution from OATP1B3, NTCP and OAT3.

Robert Elsby et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.